---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-25-000039"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T05:22:05.035991+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Lisata extends cash runway from Q3 2026 to Q4 2026

## Summary
- Company now expects current cash to fund operations into Q4 2026, versus prior Q3 2026 estimate.
- As of March 31, 2025, cash, cash equivalents and marketable securities were approximately $25.8 million.
- Revised guidance based on existing and planned activities; no other material changes disclosed.

## SEC filing metadata
- accession: 0000320017-25-000039
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001725000039/0000320017-25-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001725000039/clbs-20250617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-25-000039
- JSON: https://secwatch.observer/filing/0000320017-25-000039.json
- Plain text: https://secwatch.observer/filing/0000320017-25-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.